Glenmark to Pay $25 Million in False Claims Settlement
Glenmark Pharmaceuticals Inc. USA has agreed to pay $25 million to resolve allegations of violating the False Claims Act. The settlement, announced Wednesday by the U.S. Department of Justice, stems from accusations that the New Jersey-based company engaged in price-fixing of a popular generic cholesterol medication.